<DOC>
	<DOCNO>NCT02139540</DOCNO>
	<brief_summary>Major depressive disorder ( MDD ) global medical problem significant shortcoming current therapy . Chief among delay initiation pharmacologic therapy clinical improvement symptom . Recently ketamine , NDMA-receptor antagonist show rapidly effectively reverse symptom MDD . Nitrous oxide , another NMDA-receptor antagonist , may produce effect clean side-effect profile perhaps without need intravenous access anesthesia personnel . Therefore , propose conduct pilot randomize placebo control double-blind crossover study patient receive 50 % nitrous oxide oxygen 50 % oxygen air period one hour addition standard medical therapy . Depression severity assess blind observer pre-treatment , 30 minute 2 hour post treatment use Hamilton depression rating scale .</brief_summary>
	<brief_title>Nitrous Oxide Treatment Major Depression - Pilot Study</brief_title>
	<detailed_description>We study 20 patient non-treatment resistant major depression 20 patient treatment-resistant major depression , defined failure least 2 antidepressant current depressive episode 3 lifetime medication failure .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Nitrous Oxide</mesh_term>
	<criteria>1 . Adults 1865 year age 2 . Major depressive disorder without psychosis determine structure interview use MiniInternational Neuropsychiatric Interview ( MINI ) . ( baseline ) 3 . HDRS21 score &gt; 18 4 . Good command English language History : 1 . Bipolar disorder 2 . Schizoprenia 3 . Schizoaffective disorder 4 . Obsessivecompulsive disorder , panic disorder 5 . Substance abuse dependence ( except remote substance abuse dependence remission least 1 year prior study except nicotine use disorder ) 6 . Axis II diagnosis may interfere patient 's ability improve nitrous oxide 7 . Acute medical illness may pose subject risk nitrous oxide administration 8 . Active suicidal intention ( inability contract safety ) 9 . Active psychotic symptom 10 . Patients significant pulmonary disease and/or require supplemental oxygen 11 . Contraindication use nitrous oxide : 1 . Pneumothorax 2 . Bowel obstruction 3 . Middle ear occlusion 4 . Elevated intracranial pressure 5 . Chronic cobalamin and/or folate deficiency treat folic acid vitamin B12 6 . Pregnant patient 7 . Breastfeeding woman 12 . Previous administration NMDAreceptor antagonist ( e.g. , ketamine ) within last 3 month 13 . Current electroconvulsive therapy treatment 14 . Any active suicidal ideation , intention , planning ( clinical assessment suicidality use )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Treatment</keyword>
</DOC>